Pacira Pharmaceuticals buy Truist Financial Co.
Start price
07.11.25
/
50%
€19.10
Target price
07.11.26
€24.27
Performance (%)
-13.09%
Price
16.01.26
€17.70
Summary
This prediction is currently active. The prediction for Pacira Pharmaceuticals disappoints with a performance of -13.09%. This prediction currently runs until 07.11.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | -13.235% | -13.235% |
| iShares Core DAX® | 0.191% | 4.892% |
| iShares Nasdaq 100 | -0.614% | 2.901% |
| iShares Nikkei 225® | 0.599% | 7.404% |
| iShares S&P 500 | -0.036% | 3.489% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences (NASDAQ:PCRX) had its price target lowered by analysts at Truist Financial Corporation from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.90
25.07.25
25.07.25
€25.55
25.07.26
25.07.26
-3.17%
16.01.26
16.01.26
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.40
25.07.24
25.07.24
€27.62
25.07.25
25.07.25
2.17%
26.07.25
26.07.25